These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31228624)

  • 1. Giant Secondary Overgrowth of Type-1 Pulmonary Cystic Airway Malformation Upon Development of Anaplastic Lymphoma Kinase-Rearranged Adenocarcinoma.
    Pelosi G; Vandoni A; Meroni A; Uslenghi E; Callipo F; Papanikolaou N; Cannone M; Balladore E; D'Amico ME; Harari S; Zompatori M; Incarbone M
    J Thorac Oncol; 2019 Nov; 14(11):2019-2022. PubMed ID: 31228624
    [No Abstract]   [Full Text] [Related]  

  • 2. Echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement in congenital pulmonary airway malformation.
    Tetsumoto S; Kijima T; Morii E; Goya S; Minami T; Hirata H; Takahashi R; Kohmo S; Inoue K; Nagatomo I; Takeda Y; Kida H; Tachibana I; Kumanogoh A
    Clin Lung Cancer; 2013 Jul; 14(4):457-60. PubMed ID: 23357247
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
    Mattar MS; Chang J; Benayed R; Halpenny D; Powers A; Kleiner DE; Drilon A; Kris MG
    Clin Lung Cancer; 2020 Jan; 21(1):e25-e29. PubMed ID: 31690489
    [No Abstract]   [Full Text] [Related]  

  • 4. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
    Fang W; Gan J; Hong S; Lu F; Zhang L
    J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma.
    Zhang H; Shan G; Cai B; Bi G; Chen Z; Liang J; Besskaya V; Zheng Y; Guo W; Wang L; Xu S; Zhan C
    Thorac Cancer; 2021 Nov; 12(22):3011-3018. PubMed ID: 34596344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenocarcinoma in situ in type I congenital pulmonary airway malformation.
    Santosham R; Santosham R; Tirunagari V; Jacob SS
    Asian Cardiovasc Thorac Ann; 2019 Sep; 27(7):606-608. PubMed ID: 31226882
    [No Abstract]   [Full Text] [Related]  

  • 7. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
    J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract]   [Full Text] [Related]  

  • 8. EGFR mutation of adenocarcinoma in congenital cystic adenomatoid malformation/congenital pulmonary airway malformation: a case report.
    Hasegawa M; Sakai F; Arimura K; Katsura H; Koh E; Sekine Y; Hiroshima K
    Jpn J Clin Oncol; 2014 Mar; 44(3):278-81. PubMed ID: 24482415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma.
    Nakashima T; Nonoshita T; Hirata H; Inoue K; Nagashima A; Yoshitake T; Asai K; Shioyama Y
    In Vivo; 2020; 34(1):247-253. PubMed ID: 31882485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma.
    He W; Xu D; Wang Z; Wu H; Xiang X; Tang B; Jiang W; Cui Y; Wang H; Jiang N; Sun Y; Chen Y; Li S; Hou M; Zhang Y; Wang L; Ke ZF
    J Transl Med; 2019 Jan; 17(1):32. PubMed ID: 30658713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas.
    Kim H; Lee HJ; Hong H; Kim YJ; Kim KG; Jeon YK; Kim YT
    Thorac Cancer; 2019 Jul; 10(7):1619-1627. PubMed ID: 31215177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
    Baglivo S; Ricciuti B; Ludovini V; Metro G; Siggillino A; De Giglio A; Chiari R
    J Thorac Oncol; 2018 Aug; 13(8):e145-e147. PubMed ID: 30049377
    [No Abstract]   [Full Text] [Related]  

  • 15. Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
    Monzonís X; Arriola E
    J Thorac Oncol; 2019 Nov; 14(11):e247-e248. PubMed ID: 31668321
    [No Abstract]   [Full Text] [Related]  

  • 16. [Crizotinib treatment for a lung adenocarcinoma patient with anaplastic lymphoma kinase gene rearrangement and disseminated intravascular coagulation].
    Wang S; Li SM; Wu X; Zhu H; Wang QM
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1195-1196. PubMed ID: 34794223
    [No Abstract]   [Full Text] [Related]  

  • 17. Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
    Fan J; Dai X; Wang Z; Huang B; Shi H; Luo D; Zhang J; Cai W; Nie X; Hirsch FR
    Clin Lung Cancer; 2019 Jul; 20(4):e517-e530. PubMed ID: 31138506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases.
    Fares AF; Lok BH; Zhang T; Cabanero M; Lau SCM; Stockley T; Patel D; Bradbury PA; Sacher A; Yasufuku K; Morash BA; Sabatini PJB; Nguyen LN; Leighl NB; Tsao MS; Shepherd FA; Liu G; Martins-Filho SN; Pal P
    Lung Cancer; 2020 Aug; 146():350-354. PubMed ID: 32546380
    [No Abstract]   [Full Text] [Related]  

  • 19. Mucinous Adenocarcinoma With Intrapulmonary Metastasis Harboring KRAS and GNAS Mutations Arising in Congenital Pulmonary Airway Malformation.
    de Cordova XF; Wang H; Mehrad M; Eisenberg R; Johnson J; Wei Q; Borinstein S; Danko ME; Liang J
    Am J Clin Pathol; 2021 Jul; 156(2):313-319. PubMed ID: 33609098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucinous Cell Clusters in Infantile Congenital Pulmonary Airway Malformations Mimic Adult Mucinous Adenocarcinoma But Are Not Associated With Poor Outcomes When Appropriately Resected.
    Nelson ND; Litzky LA; Peranteau WH; Pogoriler J
    Am J Surg Pathol; 2020 Aug; 44(8):1118-1129. PubMed ID: 32349050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.